Press Releases

2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

Dec 2013 | Download as pdf

Soluble Therapeutics Inc. has a second cash infusion that will help the company continue its work in protein-based pharmaceuticals as well as more

Dec 2013 | Download as pdf

StemBioSys, a San Antonio-based bioscience startup, is looking to raise $8 million in new Series A investor funding. The company has already secured more than $3 million of that amount.

Targeted Technology Fund II will likely invest at least $2 million in StemBioSys, according to the managing partner of the venture fund, Paul Castella, PhD.

“As StemBioSys grows, it’s very likely that it will need significant capital. More than we can provide,” Castella says. “To really knock it out of the park, they may need $20 million in the next round.”

StemBioSys CEO Peter Savas says the support Targeted Technology Fund provides StemBioSys will help the company attract serious attention from other potential investors as it works to expand stem cell research and strengthen its intellectual property.

Savas was in New York recently and attended a meeting that included CEOs of life sciences companies and representatives from a number of high-profile venture funds.

“What I thought was interesting at the meeting is that everyone agrees the growth of the regenerative medicine sector is coming,” Savas tells me. “Everybody absolutely agrees that San Antonio has assets. I have probably close to a dozen venture funds who now want to understand more about our Series B (funding round).”

One of the major challenges in stem-cell research is that a large quantity and high quality of these cells are needed to pursue novel ways of attacking diseases. StemBioSys has developed a technology platform which isolates and expands populations of high-quality stem cells.

Late last month, I reported that City Council approved a $200,000 grant that will be distributed through the San Antonio Economic Development Corp. to StemBioSys that will support additional stem cell research, as well as a development and manufacturing partnership between StemBioSys and BioBridge Global, a separate San Antonio entity. back

29 Nov 2013 | Download as pdf

Medical-device firm Xenex attracts big Investment. When Rackspace Hosting co-founder Morris Miller more

25 Nov 2013 | Download as pdf

Xenex CEO expects 2013 revenues to be north of $20 Million. Xenex Disinfection Services’ Morris Miller expects more

21 Nov 2013 | Download as pdf

Xenex Secures $11.3 Million in Funding; Superbug Zapping Robot Enhances Patient Safety by Eliminating Pathogens that Cause Hospital Infections more

14 Nov 2013 | Download as pdf

DNAtrix Announces Treatment of First Patient in Study with Recurrent Glioblastoma Using DNX-2401 and Temozolomide more

Sept 2013 | Download as pdf

Medical Innovation iTClamp Hemorrhage Control System Used for First Time in United States more

Aug 2013 | Download as pdf

BiO2 Medical Executes Full Commercialization in the United Kingdom Partnering with United Drug Medical (UDM) as an Exclusive Distributor for the Angel® Catheter more

July 2013 | Download as pdf

DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus more

July 2013 | Download as pdf

ArthroCare Announces Acquisition of ENTrigue Surgical, Inc more

May 2013 | Download as pdf

Vidacare projects big revenue spike for 2013 more

May 2013 | Download as pdf

BiO2 Medical's IDE Application for the Angel(TM) Catheter Receives FDA Approval more

May 2013 | Download as pdf

Medical Device Firm iTraumaCareTM Receives FDA 510(k) Clearance for iTClampTM Hemorrhage Control System more

May 2013 | Download as pdf

BiO2 Medical's IDE Application for the Angel(TM) Catheter Receives FDA Approval more

March 2013 | Download as pdf

Woman, 80, gets new blood clot prevention device more

Feb 2013 | Download as pdf

BioDtech, Inc. Issued New United States Patent more

Jan 2013 | Download as pdf

Successful Completion of Santalis Pharmaceuticals Initial Clinical Trials more